Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Provenge
 More »

  • Dendreon Gets Green Light in Europe
    by allowing the commercialization of Provenge in all 28 EU countries as well as ... Dendreon has defended its pricing of Provenge by citing its novelty as a first-in-class, ...
    9-17-2013
  • Vaccine Advances Drive Differentiation
    ... and the EU." Dendreon focuses on activated cellular immunology, having developed Provenge as a treatment for metastatic castrate resistant disease. "In patients with prostate ...
    6-1-2013
  • Cancer's Bitter Medicine
    ... when it launched prostate cancer drug Provenge with a $93,000 price tag that investors ... We believe that Provenge is fairly and appropriately priced based upon the therapeutic ...
    5-21-2013
  • Bayer Prostate Cancer Drug Gains FDA Approval
    ... Also approved in recent years for prostate cancer have been troubled Dendreon's pricey Provenge, which has failed to live up to lofty initial sales expectations; and Johnson & ...
    5-16-2013
  • Dendreon, Plaintiffs Settle Class-Action Suit for $40M
    its finances, business operations, and prospects for its prostate cancer drug Provenge. ... only $49.6 million in company sales due to lower-than-expected demand for Provenge. ...
    3-18-2013
  • Top 10 Biopharma Layoffs of 2012
    ... companies of similar size and complexity, following weaker-than-anticipated sales of Provenge Announced: Initial layoffs announced July 30, 2012 and planned to occur over a ...
    3-15-2013
  • Rise of Cell-Based Immunotherapy
    ... Provenge merely adds a survival advantage to hormone-refractory prostate cancer, but does ... success of Dendreon's launch of Provenge, the FDA's approval of this ...
    3-1-2013
  • Dendreon Profits Shrink Despite Product Revenue Gain
    what it calls the "significant need" for patient education and awareness of Provenge. ... will be expanding its clinical data, with the apparent aim of expanding use of Provenge. ...
    2-25-2013
  • Top 10 Biopharma Layoffs of 2012
    size and complexity, following weaker-than-anticipated sales of prostate cancer drug Provenge Announced: Initial layoffs announced July 30, 2012 and planned to occur over a ...
    2-15-2013
  • Troubled Dendreon Sells Off NJ Plant
    The company said at the time it would consolidate Provenge production in its plants in ... $78 million in sales for its sole product Provenge, up 27% from the year-ago quarter. ...
    12-20-2012
  • Optimizing Cell Lines Improves Production-Really!
    ... Two approved drugs produced in insect cells have been approved in the U.S: the human papillomavirus vaccine Cerevex, and the prostate cancer immunomodulatory agent Provenge. | ...
    11-15-2012
  • Getting Cancer Immunotherapeutics Approved
    to date in the U.S. In 2010, Dendreon's Provenge, an autologous prostate cancer vaccine, ... to pretreatment was eightfold higher in Provenge-treated patients (16.9 v 1.99; P While ...
    11-13-2012
  • Cellular Therapy Wave Finally Cresting
    ... BioDfence, Provenge, Carticel, Epicel, Nucel, Appligraf, GINTUIT, Trinity, Grafix, DeNovoET, Prokera, and AmnioGraft. As the only cell-based immune therapy, Provenge falls out of ...
    11-1-2012
  • Will FDA Bid Adieu to Auld Lang Syne and Open Up to New Drugs...
    ... Provenge, the innovative anticancer vaccine approved this year, received an initial ... A complication is the approval of Provenge (a ~$93,000 prostate cancer treatment) around ...
    9-5-2012
  • Not-So-Diplomatic Immunity
    ... The field of therapeutic vaccines-such as cancer vaccines-is reaching maturity. Indeed, the provocatively named "Provenge" vaccine has just been approved by the FDA, and several ...
    9-5-2012

  • Journal Articles

  • Steady Advance of Stem Cell Therapies: Report from the 2011 World...
    Melanie Swan
    Rejuvenation Research
    Dozens of companies are developing therapeutic solutions that are in different stages of clinical use and clinical trials. Some high-profile therapies include Dendreon's Provenge ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll